Skip to main content

Table 5 Clinical course of the gefitinib-responders who achieved PD, underwent chemotherapy, and rechallenged with gefitinib

From: Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

No.

Chemotherapy regimen after failure of gefitinib

Best response of the chemotherapy

Response of gefitinib rechallenge

Time to re-progression (month)

5

GEM+VNR

PR

PR

6.2

6

GEM+VNR

PD

SD

7.8

7

GEM+DTX

SD

PD

0.6

8

CBDCA+CPT-11 → AMR → S-1

SD

SD

1.9+

9

DTX

SD

SD

4.3+

10

DTX

SD

NE

0.9+

  1. "Rechallenge" of gefitinib indicates restarting gefitinib after cessation of gefitinib followed by other chemotherapy. GEM, gemcitabine; VNR, vinorelbine; DTX, docetaxel; CBDCA, carboplatin; CPT-11, irinotecan; AMR, amrubicin; Time to re-progression, time to progression from the date of rechallenging gefitinib; +, still continuing the response at the last date of follow-up
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us